National Bank of Canada FI Sells 211,120 Shares of Illumina, Inc. (NASDAQ:ILMN)

National Bank of Canada FI cut its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 86.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,097 shares of the life sciences company's stock after selling 211,120 shares during the quarter. National Bank of Canada FI's holdings in Illumina were worth $4,447,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Industrial Alliance Investment Management Inc. bought a new stake in Illumina during the 2nd quarter valued at $34,000. Massmutual Trust Co. FSB ADV grew its position in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. Private Trust Co. NA raised its stake in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock valued at $62,000 after purchasing an additional 212 shares during the period. Focused Wealth Management Inc purchased a new stake in Illumina during the 3rd quarter worth about $63,000. Finally, Hollencrest Capital Management bought a new position in Illumina in the 3rd quarter worth about $63,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Trading Down 1.7 %

NASDAQ ILMN traded down $2.56 on Friday, hitting $143.87. The company's stock had a trading volume of 1,799,976 shares, compared to its average volume of 2,006,513. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The firm has a market cap of $22.82 billion, a P/E ratio of -14.70 and a beta of 1.11. The company's 50-day simple moving average is $144.22 and its 200 day simple moving average is $128.02.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the business earned $0.33 EPS. The company's revenue for the quarter was down 3.5% on a year-over-year basis. Research analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on ILMN shares. HSBC raised shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. Piper Sandler decreased their price target on shares of Illumina from $195.00 to $185.00 and set an "overweight" rating on the stock in a report on Monday, November 11th. Morgan Stanley reissued an "equal weight" rating and set a $156.00 price objective on shares of Illumina in a research note on Tuesday, November 12th. Robert W. Baird upped their target price on Illumina from $124.00 to $139.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 6th. Finally, Canaccord Genuity Group lifted their price target on Illumina from $130.00 to $145.00 and gave the company a "hold" rating in a research report on Tuesday, November 5th. Nine analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Illumina has an average rating of "Moderate Buy" and an average price target of $165.86.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.